Defence Therapeutics Announces Warrant Terms Amendment

Core Viewpoint - Defence Therapeutics Inc. has announced an amendment to the terms of 800,000 Common Share purchase warrants, extending the expiry date by 12 months and reducing the exercise price to $0.75 per share [1]. Group 1: Warrant Amendments - The company is extending the expiry date of 775,000 warrants from October 30, 2026, to October 30, 2027, and for 25,000 warrants from November 29, 2026, to November 29, 2027 [1]. - The original exercise price of $1.00 has been reduced to $0.75 for both sets of warrants [1]. - None of the warrants have been exercised as of the announcement date [1]. Group 2: Company Overview - Defence Therapeutics is a publicly traded biotechnology company focused on improving cancer treatment efficacy and safety [2]. - The company utilizes its Accum® precision drug delivery platform to enhance the potency of antibody-drug conjugates (ADCs) and other complex biologics at lower doses [2]. - The goal of the company is to reduce side effects and improve access to advanced therapies through cutting-edge science and collaborations with pharmaceutical and biotech partners [2].